Dr Reddys launches cholesterol drug in US
The drug is a bioequivalent generic version of Pfizer's Lipitor tablets in the US market
Pharma major Dr Reddy's Laboratories today said that it has launched Atorvastatin calcium tablets, a bioequivalent generic version of Lipitor tablets in the US market.
The company has launched Atorvastatin calcium tablets in 10 mg, 20 mg, 40 mg and 80 mg, a bioequivalent generic version of Lipitor tablets in the US market on July 17.
The launch was followed by the approval by the US Food & Drug Administration (USFDA) of Dr Reddy's ANDA for atorvastatin calcium tablets, a company statement said here.
The Lipitor brand had US sales of approximately $8.07 billion for the most recent twelve months ending March 2012 according to IMS Health.
Dr Reddy's Atorvastatin calcium tablets are available in bottle count sizes of 90 and 500, the release said.
Last year DRL entered into a settlement agreement with Pfizer to resolve litigation over cholesterol lowering Lipitor tablets. New York-based Pfizer had sued Dr Reddy's in 2009.
Read more on: